Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) and Immatics (NASDAQ:IMTX – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.
Institutional & Insider Ownership
64.8% of Werewolf Therapeutics shares are held by institutional investors. Comparatively, 64.4% of Immatics shares are held by institutional investors. 23.6% of Werewolf Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares Werewolf Therapeutics and Immatics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Werewolf Therapeutics | N/A | -166.99% | -59.88% |
| Immatics | -495.71% | -47.41% | -39.45% |
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Werewolf Therapeutics | $1.88 million | 24.61 | -$60.82 million | ($0.76) | -1.25 |
| Immatics | $54.60 million | 23.63 | -$222.26 million | ($1.86) | -5.08 |
Werewolf Therapeutics has higher earnings, but lower revenue than Immatics. Immatics is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Werewolf Therapeutics has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, Immatics has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and price targets for Werewolf Therapeutics and Immatics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Werewolf Therapeutics | 1 | 4 | 2 | 0 | 2.14 |
| Immatics | 1 | 1 | 6 | 0 | 2.62 |
Werewolf Therapeutics currently has a consensus target price of $4.00, indicating a potential upside of 320.17%. Immatics has a consensus target price of $20.60, indicating a potential upside of 118.22%. Given Werewolf Therapeutics’ higher probable upside, research analysts plainly believe Werewolf Therapeutics is more favorable than Immatics.
Summary
Werewolf Therapeutics beats Immatics on 8 of the 14 factors compared between the two stocks.
About Werewolf Therapeutics
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
About Immatics
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Receive News & Ratings for Werewolf Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Werewolf Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
